Arden Trust’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Arden Trust’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-14	Closed	–	–	771
2020 Q1	$0	Buy	+14	New	+$304	﹤0.01%	815

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Arden Trust's ITCI Position: Q2 2020 in Review

Arden Trust sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2020, closing a stake of 14 shares.

Arden Trust first reported a position in ITCI in Q1 2020 and held it in 1 quarter. The position peaked at $0 in Q1 2020. 149 funds tracked by Wall St. Rank hold ITCI as of Q2 2020.

Arden Trust reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2020 after selling out during the quarter.
Arden Trust sold 14 Intra-Cellular Therapies Inc. shares in Q2 2020.
Arden Trust first reported a position in Intra-Cellular Therapies Inc. in Q1 2020 and held it in 1 quarter.
Arden Trust's Intra-Cellular Therapies Inc. position peaked at $0 in Q1 2020.
149 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2020.

Based on Arden Trust's 13F filing for Q2 2020, filed 9 Jul 2020.